Table 4.

The prevalence and distribution of BRAF V600E and KRAS (codons 12/13 and 59/61) mutations according to the type of neoplasm

	BRAFV 600E	KRAS (all)	KRAS c12/13	KRAS c59/61	Either BRAF or KRAS
Serrated adenocarcinomas (n = 42)
No adjacent adenoma component (n = 14)
With mutation/all	6/14	3/14	2/14	1/14	9/14
%	42.9	21.4	14.3	7.1	64.3
With adjacent serrated adenoma (n = 28)
With mutation/all	8/28	16/28	15/28	1/28	24/28
%	28.6	57.1	53.6	3.6	85.7
All (n = 42)
With mutation/all	14/42	19/42	17/42	2/42	33/42
%	33.3	45.2	40.5	4.8	78.6
Matched non-serrated carcinomas (n = 32)
With mutation/all	0/32	13/32	12/32	1/32	13/32
%	0	40.6	37.5	3.1	40.6
P	<0.001	0.894	1.00	0.842	<0.001
All non-serrated carcinomas (n = 59)
With mutation/all	0/59	16/59	15/59	1/59	16/59
%	0	27.1	25.4	1.7	27.1
P	<0.001	0.002	0.002	0.848	<0.001
Serrated adenomas (n = 17)
With mutation/all	7/17	7/17	6/17	1/17	14/17
%	41.2	41.2	35.3	5.9	82.4
Non-serrated adenomas (n = 9)
With mutation/all	0/9	1/9	1/9	0/9	1/9
%	0	11.1	11.1	0	11.1
P	0.058	0.243	0.453	1	<0.001
Serrated adenomas adjacent to cancer (n = 9)
With mutation/all	2/9	4/9	3/9	1/9	6/9
%	22.2	44.4	33.3	11.1	66.7
P	0.068	0.353	0.6	0.436	0.001